Markets
Inovio Pharmaceuticals, Inc. (INO)
INONASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.51
+0.2950 (+24.28%) today
Closed, Nov 9, 4:00 PM ET
+24.28% 1D
- Market cap
- $166.37m
- P/E
- –
- EPS, last 4 quarters
- $-0.4800
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.5632 to $2.72
- Average volume
- 11.47m
- Previous close
- $1.22
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $5.67, +275.5% from here
$4.00now $1.51$8.00
Earnings
next estimate $-0.2000Next report
Sep 2025
+13.7%
Dec 2025
+183.8%
Mar 2026
+6.7%
Jun 2026
+72.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$21.21m | -$17.48m | -$21.95m | -$18.63m |
| Net income | -$45.50m | $3.77m | -$19.68m | -$6.01m |
News
8 latest- Inovio Pharmaceuticals, Inc. Enters Underwriting Agreement for Public Offering Expected to Yield Net Proceeds of Approximately $80.5 millionFintel · 15 hours ago
- Inovio Pharmaceuticals Consensus Price Target Raised 121.05% to $7.14Fintel · 19 hours ago
- INOVIO Prices $75 Mln Public Offering With Shares At $1.05 Each; Stock Down 21% Premarket RTTNews · 4 days ago
- Healthcare Stocks Trade Higher: INO Surges 245%, IDXX Gains Over 20%, TEM Rises 12% RTTNews · Nov 2, 2026
- Inovio Wins FDA Approval for VOCERYQ, Its First Commercial ProductMarketBeat · Nov 2, 2026
- Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?Zacks · Nov 2, 2026
- INOVIO Pharma Soars As FDA Grants Accelerated Approval For VOCERYQ In Adult RRP RTTNews · Oct 30, 2026
- FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast CancerZacks · Oct 8, 2026
The company
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- inovio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.